Fever News and Research

RSS

AACR International Conference on Frontiers in Cancer Prevention Research to be held from Oct. 16-19

The 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research will bring together scientists, survivors and patient advocates to share the latest science on cancer prevention.

18 Sep 2012

Compelling data from two ITS Flunisyn Phase I clinical trials against multiple strains of influenza A

Immune Targeting Systems Limited, an emerging leader in the development of vaccines that promote T-cell responses against viruses and cancers, today announces compelling data from two Phase I clinical trials of FlunisynTM, the Company's lead vaccine programme which elicits potent immune responses against multiple strains of influenza-A virus.

18 Sep 2012

FDA clears Meridian Bioscience’s new illumigene Group A Strep test

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it has received FDA clearance for a new molecular diagnostic test for Group A Streptococcus on the illumigene platform.

18 Sep 2012

Orthopedists should suspect necrotizing fasciitis in patients with out of proportion pain

Dr. Russell Russo, an Orthopedic Surgeon at LSU Health Sciences Center New Orleans, and other researchers stress that orthopedists should have a high index of suspicion for necrotizing fasciitis, or flesh-eating bacterial infection, in every patient with pain or other symptoms that are out of proportion to the initial diagnosis. Their recommendations are published in the September 2012 issue of Orthopedics Today.

17 Sep 2012

New test to assess viral load of cytomegalovirus

Roche announced today the commercial availability of a new test to assess a patient's viral load of cytomegalovirus (CMV). Physicians use information from the test to help them manage patients who have been diagnosed with CMV disease, specifically patients with an immune system that has been suppressed for solid organ transplantation.

From Roche Sequencing and Life Science 17 Sep 2012

Ebola outbreak in DRC responsible for as many as 31 deaths, according to revised count

"An outbreak of Ebola hemorrhagic fever has claimed possibly as many as 31 lives in the northeast of the Democratic Republic of Congo since May, Health Minister Felix Kabange Numbi said Thursday," Agence France-Presse reports.

15 Sep 2012

Clinical trial results signal 'promise, unresolved challenges' in finding effective dengue vaccine

The first-ever results from a dengue virus vaccine clinical trial aimed at showing effectiveness "provide signals rather than definitive answers, and a mixture of both promise and unresolved challenges," Orin Levine, executive director of the International Vaccine Access Center, and Ciro de Quadros, executive vice president of the Sabin Vaccine Institute, write in the Huffington Post "Impact" blog.

14 Sep 2012

Leading dengue fever vaccine candidate 30% effective in first large clinical trial

"The leading candidate to become the world's first vaccine against dengue fever was only 30 percent effective in its first large clinical trial, dealing at least a temporary setback to efforts to control a disease that threatens half the world's population," the New York Times reports.

12 Sep 2012

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Santarus, Inc. today announced that its Phase III clinical study to evaluate the safety and efficacy of the investigational drug, rifamycin SV MMX, met the primary endpoint of reducing time to last unformed stool (TLUS) in patients with travelers' diarrhea.

12 Sep 2012

Individuals without capacity excluded from potentially beneficial trials

Individuals who lack the capacity to consent to taking part in clinical trials could be missing out on the opportunity to receive potentially beneficial interventions, shows UK research.

11 Sep 2012

Strep throat should be treated with penicillin or amoxicillin: IDSA guidelines

Although people often say they have "strep" throat, most sore throats actually are caused by a virus, not streptococcus bacteria, and shouldn't be treated with antibiotics, suggest guidelines published by the Infectious Diseases Society of America (IDSA). Antibiotics are ineffective against viruses.

11 Sep 2012

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

A synthetic, anti-inflammatory and anti-allergic family of drugs to combat a variety of illnesses while avoiding detrimental side effects has been developed by a Hebrew University of Jerusalem researcher.

7 Sep 2012

Durata completes target enrollment in dalbavancin Phase 3 trials for abSSSI

Durata Therapeutics today announced that it has completed its target enrollment for DISCOVER 1 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response"), one of two ongoing, global, Phase 3 clinical trials of Durata's lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin structure infections (abSSSI).

7 Sep 2012

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

Antibiotics are medicines used to treat infections or diseases caused by bacteria, such as some respiratory tract infections (including pneumonia and whooping cough), urinary tract infections, skin infections and infected wounds.

6 Sep 2012

WHO releases dengue strategy report, sets goal of cutting related deaths in half by 2020

"Saying dengue virus infections and deaths have mushroomed in recent years, the World Health Organization (WHO) recently released a strategy report that sets a goal of cutting deaths in half and reducing cases by 25 percent over the next eight years," CIDRAP reports.

6 Sep 2012

People need to protect themselves against West Nile virus

As this year's threat from the West Nile virus continues, one infectious diseases expert at the University of Alabama at Birmingham says a vaccine is not in our near future, so people need to protect themselves.

5 Sep 2012

Strong antiviral antibody response observed in oral administration of Flucide

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, led to strong antiviral antibody response. The antibody response with Oral administration was stronger than that with IV administration and was substantially greater than that observed with oseltamivir.

5 Sep 2012

Fever News and Research

AACR International Conference on Frontiers in Cancer Prevention Research to be held from Oct. 16-19

Compelling data from two ITS Flunisyn Phase I clinical trials against multiple strains of influenza A

FDA clears Meridian Bioscience’s new illumigene Group A Strep test

Orthopedists should suspect necrotizing fasciitis in patients with out of proportion pain

New test to assess viral load of cytomegalovirus

Ebola outbreak in DRC responsible for as many as 31 deaths, according to revised count

Clinical trial results signal 'promise, unresolved challenges' in finding effective dengue vaccine

Leading dengue fever vaccine candidate 30% effective in first large clinical trial

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Individuals without capacity excluded from potentially beneficial trials

Strep throat should be treated with penicillin or amoxicillin: IDSA guidelines

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

Durata completes target enrollment in dalbavancin Phase 3 trials for abSSSI

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

WHO releases dengue strategy report, sets goal of cutting related deaths in half by 2020

People need to protect themselves against West Nile virus

Strong antiviral antibody response observed in oral administration of Flucide

FDA approves Bosulif to treat chronic myelogenous leukemia

Scientists succeed in clarifying molecular signature of hantaviruses

Western Schools offers new 4th Edition West Nile Virus continuing education course for nurses

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News